Lu Lu

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3475176/publications.pdf

Version: 2024-02-01

229 papers	13,790 citations	41258 49 h-index	31759 101 g-index
240 all docs	240 docs citations	240 times ranked	20224 citing authors

#	Article	IF	Citations
1	Early Treatment of High-Risk Hospitalized Coronavirus Disease 2019 (COVID-19) Patients With a Combination of Interferon Beta-1b and Remdesivir: A Phase 2 Open-label Randomized Controlled Trial. Clinical Infectious Diseases, 2023, 76, e216-e226.	2.9	15
2	Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human Î²-Coronavirus Infection. Journal of Medicinal Chemistry, 2022, 65, 2809-2819.	2.9	9
3	Viral Entry Inhibitors Targeting Six-Helical Bundle Core against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins. Current Medicinal Chemistry, 2022, 29, 700-718.	1.2	6
4	Impact of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variant-Associated Receptor Binding Domain (RBD) Mutations on the Susceptibility to Serum Antibodies Elicited by Coronavirus Disease 2019 (COVID-19) Infection or Vaccination. Clinical Infectious Diseases, 2022, 74, 1623-1630.	2.9	42
5	A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases. Acta Pharmaceutica Sinica B, 2022, 12, 1652-1661.	5.7	24
6	An ultrapotent pan-Î²-coronavirus lineage B (Î²-CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. Protein and Cell, 2022, 13, 655-675.	4.8	25
7	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. Cell Research, 2022, 32, 269-287.	5.7	54
8	Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. Emerging Microbes and Infections, 2022, 11, 543-547.	3.0	57
9	Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature, 2022, 603, 693-699.	13.7	460
10	A Toxin-Conjugated Recombinant Protein Targeting gp120 and gp41 for Inactivating HIV-1 Virions and Killing Latency-Reversing Agent-Reactivated Latent Cells. MBio, 2022, 13, e0338421.	1.8	4
11	Dissolving microneedle-encapsulated drug-loaded nanoparticles and recombinant humanized collagen type III for the treatment of chronic wound via anti-inflammation and enhanced cell proliferation and angiogenesis. Nanoscale, 2022, 14, 1285-1295.	2.8	29
12	Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant. Cell Research, 2022, 32, 404-406.	5.7	31
13	Neutralizing SARS-CoV-2 by dimeric side chain-to-side chain cross-linked ACE2 peptide mimetics. Chemical Communications, 2022, 58, 1804-1807.	2.2	3
14	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. Vaccines, 2022, 10, 72.	2.1	13
15	Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. Vaccines, 2022, 10, 160.	2.1	33
16	Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model. Emerging Microbes and Infections, 2022, 11, 368-383.	3.0	33
17	Microfibrillated cellulose-enhanced carboxymethyl chitosan/oxidized starch sponge for chronic diabetic wound repair. Materials Science and Engineering C, 2022, 135, 112669.	3.8	11
18	SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerging Microbes and Infections, 2022, 11, 277-283.	3.0	308

#	Article	IF	Citations
19	An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. Journal of Clinical Investigation, 2022, 132, .	3.9	14
20	Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clinical Infectious Diseases, 2022, 75, e822-e826.	2.9	322
21	A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant. Cell Research, 2022, 32, 495-497.	5.7	24
22	Effect of Different Adjuvants on Immune Responses Elicited by Protein-Based Subunit Vaccines against SARS-CoV-2 and Its Delta Variant. Viruses, 2022, 14, 501.	1.5	15
23	The Analogs of Furanyl Methylidene Rhodanine Exhibit Broad-Spectrum Inhibitory and Inactivating Activities against Enveloped Viruses, including SARS-CoV-2 and Its Variants. Viruses, 2022, 14, 489.	1.5	7
24	Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines. MSphere, 2022, 7, e0091521.	1.3	9
25	Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell, 2022, 185, 1389-1401.e18.	13.5	82
26	A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern. Viruses, 2022, 14, 597.	1.5	22
27	A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern. Viruses, 2022, 14, 549.	1.5	13
28	A genome-scale screen for synthetic drivers of T cell proliferation. Nature, 2022, 603, 728-735.	13.7	84
29	A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile. Pharmaceuticals, 2022, 15, 424.	1.7	0
30	Interferon-gamma inhibits influenza A virus cellular attachment by reducing sialic acid cluster size. IScience, 2022, 25, 104037.	1.9	10
31	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. EBioMedicine, 2022, 79, 103986.	2.7	23
32	Design of artificial Î±-helical peptides targeting both gp41 deep pocket and subpocket as potent HIV-1 fusion inhibitors. European Journal of Medicinal Chemistry, 2022, 236, 114336.	2.6	1
33	Injectable multifunctional hyaluronic acid/methylcellulose hydrogels for chronic wounds repairing. Carbohydrate Polymers, 2022, 289, 119456.	5.1	40
34	Coronavirus Entry Inhibitors. Advances in Experimental Medicine and Biology, 2022, 1366, 101-121.	0.8	3
35	A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life. Viruses, 2022, 14, 655.	1.5	8
36	Longâ€acting Protective Ocular Surface by Instilling Adhesive Dualâ€antiviral Nanoparticles. Advanced Healthcare Materials, 2022, , 2200283.	3.9	6

#	Article	IF	Citations
37	Up or down: where comes Omicron?. Cell Research, 2022, 32, 601-602.	5.7	5
38	Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters. Science, 2022, 377, 428-433.	6.0	113
39	Neutralization mechanism of a human antibody with pan-coronavirus reactivity including SARS-CoV-2. Nature Microbiology, 2022, 7, 1063-1074.	5.9	63
40	A broadly neutralizing antibody against SARS-CoV-2 Omicron variant infection exhibiting a novel trimer dimer conformation in spike protein binding. Cell Research, 2022, 32, 862-865.	5.7	8
41	Engineered trimeric ACE2 binds viral spike protein and locks it in â€œThree-upâ€•conformation to potently inhibit SARS-CoV-2 infection. Cell Research, 2021, 31, 98-100.	5.7	76
42	Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells. Cell, 2021, 184, 92-105.e16.	13.5	480
43	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nature Communications, 2021, 12, 866.	5.8	73
44	Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Reports, 2021, 34, 108699.	2.9	110
45	Antivirals with common targets against highly pathogenic viruses. Cell, 2021, 184, 1604-1620.	13.5	78
46	The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduction and Targeted Therapy, 2021, 6, 132.	7.1	29
47	Immunoengineered adjuvants for universal vaccines against respiratory viruses. Fundamental Research, 2021, 1, 189-192.	1.6	4
48	Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection. Molecules, 2021, 26, 1964.	1.7	4
49	Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection. Microbes and Infection, 2021, 23, 104840.	1.0	2
50	A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses. Cell and Bioscience, 2021, 11, 128.	2.1	9
51	A â€œTwo-Birds-One-Stoneâ€•Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region. Journal of Medicinal Chemistry, 2021, 64, 11460-11471.	2.9	9
52	Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation. Signal Transduction and Targeted Therapy, 2021, 6, 288.	7.1	38
53	Repurposing of a clinically used anti-HPV agent to prevent and treat SARS-CoV-2 infection as an intranasal formulation. Signal Transduction and Targeted Therapy, 2021, 6, 318.	7.1	7
54	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. EBioMedicine, 2021, 71, 103544.	2.7	38

#	Article	IF	Citations
55	A tailored extracellular matrix (ECM) - Mimetic coating for cardiovascular stents by stepwise assembly of hyaluronic acid and recombinant human type III collagen. Biomaterials, 2021, 276, 121055.	5.7	58
56	Inhibition of viral suppressor of RNAi proteins by designer peptides protects from enteroviral infection inÂvivo. Immunity, 2021, 54, 2231-2244.e6.	6.6	23
57	AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells. Cell Research, 2021, 31, 126-140.	5.7	356
58	Pan-coronavirus fusion inhibitors as the hope for today and tomorrow. Protein and Cell, 2021, 12, 84-88.	4.8	31
59	High compliance to infection control measures prevented guest-to-staff transmission in COVID-19 quarantine hotels. Journal of Infection, 2021, , .	1.7	4
60	Emerging SARS-CoV-2 variants expand species tropism to murines. EBioMedicine, 2021, 73, 103643.	2.7	127
61	25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses. International Journal of Molecular Sciences, 2021, 22, 11869.	1.8	16
62	Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha). Cell Discovery, 2021, 7, 109.	3.1	17
63	A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants. Signal Transduction and Targeted Therapy, 2021, 6, 378.	7.1	26
64	Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant. Diagnostics, 2021, 11, 2216.	1.3	6
65	Microenvironment-responsive multifunctional hydrogels with spatiotemporal sequential release of tailored recombinant human collagen type III for the rapid repair of infected chronic diabetic wounds. Journal of Materials Chemistry B, 2021, 9, 9684-9699.	2.9	26
66	Antibody Response of BNT162b2 and CoronaVac Platforms in Recovered Individuals Previously Infected by COVID-19 against SARS-CoV-2 Wild Type and Delta Variant. Vaccines, 2021, 9, 1442.	2.1	18
67	Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. Virologica Sinica, 2020, 35, 857-860.	1.2	39
68	Decoy nanoparticles protect against COVID-19 by concurrently adsorbing viruses and inflammatory cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 27141-27147.	3.3	173
69	RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduction and Targeted Therapy, 2020, 5, 282.	7.1	149
70	Evaluating the Association of Clinical Characteristics With Neutralizing Antibody Levels in Patients Who Have Recovered From Mild COVID-19 in Shanghai, China. JAMA Internal Medicine, 2020, 180, 1356.	2.6	211
71	Repurposing of Miltefosine as an Adjuvant for Influenza Vaccine. Vaccines, 2020, 8, 754.	2.1	6
72	Protein- and Peptide-Based Virus Inactivators: Inactivating Viruses Before Their Entry Into Cells. Frontiers in Microbiology, 2020, 11, 1063.	1.5	26

#	Article	IF	Citations
73	Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study. Lancet Microbe, The, 2020, 1, e111-e118.	3.4	86
74	Identification of Human Single-Domain Antibodies against SARS-CoV-2. Cell Host and Microbe, 2020, 27, 891-898.e5.	5.1	227
75	The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin. Signal Transduction and Targeted Therapy, 2020, 5, 92.	7.1	263
76	An amphipathic peptide targeting the gp41 cytoplasmic tail kills HIV-1 virions and infected cells. Science Translational Medicine, 2020, 12, .	5.8	10
77	Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases. International Journal of Molecular Sciences, 2020, 21, 3843.	1.8	37
78	Development of oncolytic virotherapy: from genetic modification to combination therapy. Frontiers of Medicine, 2020, 14, 160-184.	1.5	40
79	Inhibition of SARS-CoV-2 (previously 2019-nCoV)Âinfection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Research, 2020, 30, 343-355.	5.7	1,083
80	Sodium Copper Chlorophyllin Is Highly Effective against Enterovirus (EV) A71 Infection by Blocking Its Entry into the Host Cell. ACS Infectious Diseases, 2020, 6, 882-890.	1.8	14
81	High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerging Microbes and Infections, 2020, 9, 1664-1670.	3.0	129
82	Design, modeling and 3D printing of a personalized cervix tissue implant with protein release function. Biomedical Materials (Bristol), 2020, 15, 045005.	1.7	17
83	Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerging Microbes and Infections, 2020, 9, 382-385.	3.0	1,086
84	Pulmonary surfactantâ€"biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science, 2020, 367, .	6.0	203
85	Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cellular and Molecular Immunology, 2020, 17, 765-767.	4.8	564
86	Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection. Virologica Sinica, 2020, 35, 340-343.	1.2	10
87	Rational Design of A Novel Small-Molecule HIV-1 Inactivator Targeting Both gp120 and gp41 of HIV-1. Frontiers in Pharmacology, 2020, 11, 613361.	1.6	7
88	A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome. Cellular and Molecular Immunology, 2020, 17, 554-554.	4.8	124
89	Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection. Journal of Virology, 2019, 93, .	1.5	8
90	A Peptide-Based Virus Inactivator Protects Male Mice Against Zika Virus-Induced Damage of Testicular Tissue. Frontiers in Microbiology, 2019, 10, 2250.	1.5	10

#	Article	IF	Citations
91	Development of Protein- and Peptide-Based HIV Entry Inhibitors Targeting gp120 or gp41. Viruses, 2019, 11, 705.	1.5	30
92	Design and Biological Evaluation of m-Xylene Thioether-Stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiledâ€"Coil Fusion Complex. Journal of Medicinal Chemistry, 2019, 62, 8773-8783.	2.9	11
93	Assessment of population susceptibility to upcoming seasonal influenza epidemic strain using interepidemic emerging influenza virus strains. Epidemiology and Infection, 2019, 147, e279.	1.0	6
94	A Novel CXCR4 Targeting Protein SDF-1/54 as an HIV-1 Entry Inhibitor. Viruses, 2019, 11, 874.	1.5	8
95	Sin1/mTORC2 regulate B cell growth and metabolism by activating mTORC1 and Myc. Cellular and Molecular Immunology, 2019, 16, 757-769.	4.8	21
96	Dlg1 Maintains Dendritic Cell Function by Securing Voltage-Gated K+ Channel Integrity. Journal of Immunology, 2019, 202, 3187-3197.	0.4	10
97	A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Molecules, 2019, 24, 1134.	1.7	23
98	A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Science Advances, 2019, 5, eaav4580.	4.7	393
99	P848â€...Revisiting enfuvirtideâ€™s mechanism and designing its analog with improved activity by targeting triple sites in gp41. , 2019, , .		0
100	Erythromycin Estolate Inhibits Zika Virus Infection by Blocking Viral Entry as a Viral Inactivator. Viruses, 2019, 11, 1064.	1.5	13
101	Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. Aids, 2019, 33, 1545-1555.	1.0	16
102	IgG Fc-binding motif-conjugated HIV-1 fusion inhibitor exhibits improved potency and in vivo half-life: Potential application in combination with broad neutralizing antibodies. PLoS Pathogens, 2019, 15, e1008082.	2.1	16
103	Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity. Biochemical and Biophysical Research Communications, 2019, 508, 1018-1023.	1.0	33
104	Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4. Viruses, 2019, 11, 56.	1.5	31
105	Combining a Fusion Inhibitory Peptide Targeting the MERS-CoV S2 Protein HR1 Domain and a Neutralizing Antibody Specific for the S1 Protein Receptor-Binding Domain (RBD) Showed Potent Synergism against Pseudotyped MERS-CoV with or without Mutations in RBD. Viruses, 2019, 11, 31.	1.5	20
106	Rhinovirus respiratory tract infection in hospitalized adult patients is associated with T H 2 response irrespective of asthma. Journal of Infection, 2018, 76, 465-474.	1.7	27
107	A CCR5 antagonist-based HIV entry inhibitor exhibited potent spermicidal activity: Potential application for contraception and prevention of HIV sexual transmission. European Journal of Pharmaceutical Sciences, 2018, 117, 313-320.	1.9	9
108	The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. Protein and Cell, 2018, 9, 596-615.	4.8	37

#	Article	IF	Citations
109	AXL promotes Zika virus infection in astrocytes by antagonizing type I interferon signalling. Nature Microbiology, 2018, 3, 302-309.	5.9	129
110	Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus. Microbes and Infection, 2018, 20, 626-634.	1.0	20
111	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. Frontiers in Microbiology, 2018, 9, 2570.	1.5	6
112	The Antihistamine Drugs Carbinoxamine Maleate and Chlorpheniramine Maleate Exhibit Potent Antiviral Activity Against a Broad Spectrum of Influenza Viruses. Frontiers in Microbiology, 2018, 9, 2643.	1.5	29
113	A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. Aids, 2018, 32, 1749-1761.	1.0	11
114	Peptide-Based Membrane Fusion Inhibitors Targeting HCoV-229E Spike Protein HR1 and HR2 Domains. International Journal of Molecular Sciences, 2018, 19, 487.	1.8	63
115	Intra-amniotic Injection of Mouse Embryos. Bio-protocol, 2018, 8, e2854.	0.2	0
116	Fusion. , 2018, , 564-571.		0
117	Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1. Cellular and Molecular Immunology, 2017, 14, 568-571.	4.8	2
118	Small-molecule HIV-1 entry inhibitors targeting gp120 and gp41: a patent review (2010-2015). Expert Opinion on Therapeutic Patents, 2017, 27, 707-719.	2.4	24
119	Chemically Modified Human Serum Albumin Potently Blocks Entry of Ebola Pseudoviruses and Viruslike Particles. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	20
120	Additional molecular testing of saliva specimens improves the detection of respiratory viruses. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	101
121	HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	21
122	A novel HIV-1 gp41 tripartite model for rational design of HIV-1 fusion inhibitors with improved antiviral activity. Aids, 2017, 31, 885-894.	1.0	26
123	Visual and Motor Deficits in Grown-up Mice with Congenital Zika Virus Infection. EBioMedicine, 2017, 20, 193-201.	2.7	55
124	Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. Journal of Infection, 2017, 75, 68-71.	1.7	7
125	MERS-CoV spike protein: a key target for antivirals. Expert Opinion on Therapeutic Targets, 2017, 21, 131-143.	1.5	236
126	A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host and Microbe, 2017, 22, 471-483.e5.	5.1	48

#	Article	IF	Citations
127	Zika virus infects renal proximal tubular epithelial cells with prolonged persistency and cytopathic effects. Emerging Microbes and Infections, 2017, 6, 1-7.	3.0	34
128	Genomic signature analysis of the recently emerged highly pathogenic A(H5N8) avian influenza virus: implying an evolutionary trend for bird-to-human transmission. Microbes and Infection, 2017, 19, 597-604.	1.0	14
129	A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nature Communications, 2017, 8, 15672.	5.8	115
130	HIV-1 Env DNA prime plus gp120 and gp70-V1V2 boosts induce high level of V1V2-specific IgG and ADCC responses and low level of Env-specific IgA response: implication for improving RV144 vaccine regimen. Emerging Microbes and Infections, 2017, 6, 1-4.	3.0	2
131	Development of small-molecule viral inhibitors targeting various stages of the life cycle of emerging and re-emerging viruses. Frontiers of Medicine, 2017, 11, 449-461.	1.5	22
132	Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors. Journal of Virology, 2017, 91, .	1.5	25
133	Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerging Microbes and Infections, 2017, 6, 1-11.	3.0	41
134	Adding an Artificial Tailâ€"Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile. Molecules, 2017, 22, 1996.	1.7	13
135	Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. BioMed Research International, 2017, 2017, 1-12.	0.9	34
136	Poly(U) and CpG ameliorate the unbalanced T cell immunity and pneumonia of mice with RSV vaccine-enhanced disease. BioScience Trends, 2017, 11, 450-459.	1.1	3
137	Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles. Aids, 2016, 30, 827-838.	1.0	26
138	An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene. Emerging Microbes and Infections, 2016, 5, 1-12.	3.0	24
139	Safety evaluation of chemically modified betaâ€lactoglobulin administered intravaginally. Journal of Medical Virology, 2016, 88, 1098-1101.	2.5	9
140	A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection. Microbes and Infection, 2016, 18, 148-152.	1.0	17
141	Intranasal application of polyethyleneimine suppresses influenza virus infection in mice. Emerging Microbes and Infections, 2016, 5, 1-2.	3.0	9
142	A novel bispecific peptide HIV-1 fusion inhibitor targeting the N-terminal heptad repeat and fusion peptide domains in gp41. Amino Acids, 2016, 48, 2867-2873.	1.2	9
143	Rational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations. Scientific Reports, 2016, 6, 31983.	1.6	12
144	Site-specific Isopeptide Bridge Tethering of Chimeric gp41 N-terminal Heptad Repeat Helical Trimers for the Treatment of HIV-1 Infection. Scientific Reports, 2016, 6, 32161.	1.6	9

#	Article	IF	Citations
145	Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cellular and Molecular Immunology, 2016, 13, 180-190.	4.8	114
146	An effective strategy for recapitulating N-terminal heptad repeat trimers in enveloped virus surface glycoproteins for therapeutic applications. Chemical Science, 2016, 7, 2145-2150.	3.7	10
147	Normal human sera contain heat-sensitive factor(s) to enhance H7N9 influenza virus infection. Journal of Infection, 2016, 72, 123-125.	1.7	0
148	Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. Journal of Virology, 2016, 90, 57-67.	1.5	72
149	Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Scientific Reports, 2015, 5, 13028.	1.6	33
150	Alterations in serotonin, transient receptor potential channels and protease-activated receptors in rats with irritable bowel syndrome attenuated by Shugan decoction. World Journal of Gastroenterology, 2015, 21, 4852.	1.4	30
151	Receptor Binding Domain Based HIV Vaccines. BioMed Research International, 2015, 2015, 1-9.	0.9	5
152	Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes and Infection, 2015, 17, 142-148.	1.0	30
153	Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Research, 2015, 202, 151-159.	1.1	54
154	Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. Microbes and Infection, 2015, 17, 135-141.	1.0	5
155	Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerging Microbes and Infections, 2015, 4, 1-2.	3.0	11
156	Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. Journal of Infectious Diseases, 2015, 212, 1894-1903.	1.9	87
157	Intranasal Administration of Maleic Anhydride-Modified Human Serum Albumin for Pre-Exposure Prophylaxis of Respiratory Syncytial Virus Infection. Viruses, 2015, 7, 798-819.	1.5	11
158	Nonneutralizing Antibodies Induced by the HIV-1 gp41 NHR Domain Gain Neutralizing Activity in the Presence of the HIV Fusion Inhibitor Enfuvirtide: a Potential Therapeutic Vaccine Strategy. Journal of Virology, 2015, 89, 6960-6964.	1.5	17
159	Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection. Lancet, The, 2015, 386, S44.	6.3	3
160	An artificial peptide-based HIV-1 fusion inhibitor containing M-T hook structure exhibiting improved antiviral potency and drug resistance profile. Future Virology, 2015, 10, 961-969.	0.9	0
161	ADS-J1 Inhibits Semen-Derived Amyloid Fibril Formation and Blocks Fibril-Mediated Enhancement of HIV-1 Infection. Antimicrobial Agents and Chemotherapy, 2015, 59, 5123-5134.	1.4	21
162	De novo design of isopeptide bond-tethered triple-stranded coiled coils with exceptional resistance to unfolding and proteolysis: implication for developing antiviral therapeutics. Chemical Science, 2015, 6, 6505-6509.	3.7	9

#	Article	IF	Citations
163	Advancements in the development of subunit influenza vaccines. Microbes and Infection, 2015, 17, 123-134.	1.0	43
164	Development of therapeutics for treatment of Ebola virus infection. Microbes and Infection, 2015, 17, 109-117.	1.0	40
165	Testing of Middle East Respiratory Syndrome Coronavirus Replication Inhibitors for the Ability To Block Viral Entry. Antimicrobial Agents and Chemotherapy, 2015, 59, 742-744.	1.4	41
166	Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. Current Topics in Medicinal Chemistry, 2015, 16, 1074-1090.	1.0	61
167	HIV-1 impairs human retinal pigment epithelial barrier function: possible association with the pathogenesis of HIV-associated retinopathy. Laboratory Investigation, 2014, 94, 777-787.	1.7	22
168	Hydrophobic mutations in buried polar residues enhance HIV-1 gp41 N-terminal heptad repeatâ€"C-terminal heptad repeat interactions and C-peptidesâ€™ anti-HIV activity. Aids, 2014, 28, 1251-1260.	1.0	15
169	Synergistic Effect Resulting From Combinations of a Bifunctional HIV-1 Antagonist With Antiretroviral Drugs. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 1-6.	0.9	30
170	Exceptionally Potent Neutralization of Middle East Respiratory Syndrome Coronavirus by Human Monoclonal Antibodies. Journal of Virology, 2014, 88, 7796-7805.	1.5	212
171	Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nature Communications, 2014, 5, 3067.	5.8	324
172	ADS-J1 inhibits HIV-1 infection and membrane fusion by targeting the highly conserved pocket in the gp41 NHR-trimer. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1296-1305.	1.4	27
173	Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Research, 2014, 194, 200-210.	1.1	100
174	Artificial peptides conjugated with cholesterol and pocket-specific small molecules potently inhibit infection by laboratory-adapted and primary HIV-1 isolates and enfuvirtide-resistant HIV-1 strains. Journal of Antimicrobial Chemotherapy, 2014, 69, 1537-1545.	1.3	13
175	Conjugation of a Nonspecific Antiviral Sapogenin with a Specific HIV Fusion Inhibitor: A Promising Strategy for Discovering New Antiviral Therapeutics. Journal of Medicinal Chemistry, 2014, 57, 7342-7354.	2.9	36
176	Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3719-3723.	1.0	6
177	Peptides derived from HIVâ€1 gp120 coâ€receptor binding domain form amyloid fibrils and enhance HIVâ€1 infection. FEBS Letters, 2014, 588, 1515-1522.	1.3	19
178	A Nanoparticle-Encapsulated Non-Nucleoside Reverse-Transcriptase Inhibitor with Enhanced Anti-HIV-1 Activity and Prolonged Circulation Time in Plasma. Current Pharmaceutical Design, 2014, 21, 925-935.	0.9	14
179	Neutralization sensitivity of HIV-1 subtype Bâ€™ clinical isolates from former plasma donors in China. Virology Journal, 2013, 10, 10.	1.4	15
180	Controlling HIV sexual transmission: a major challenge for China's new leadership. Cell and Bioscience, 2013, 3, 17.	2.1	1

#	Article	IF	Citations
181	Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. Journal of Infection, 2013, 67, 156-158.	1.7	9
182	An engineered HIV-1 gp41 trimeric coiled coil with increased stability and anti-HIV-1 activity: implication for developing anti-HIV microbicides. Journal of Antimicrobial Chemotherapy, 2013, 68, 2533-2544.	1.3	32
183	Chemically modified bovine beta-lactoglobulin inhibits human papillomavirus infection. Microbes and Infection, 2013, 15, 506-510.	1.0	21
184	F(abâ€²)2 fragment of a gp41 NHR-trimer-induced IgM monoclonal antibody neutralizes HIV-1 infection and blocks viral fusion by targeting the conserved gp41 pocket. Microbes and Infection, 2013, 15, 887-894.	1.0	4
185	PA-356R is a unique signature of the avian influenza A (H7N9) viruses with bird-to-human transmissibility: Potential implication for animal surveillances. Journal of Infection, 2013, 67, 490-494.	1.7	18
186	A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. Journal of Infection, 2013, 66, 464-466.	1.7	39
187	Development of SARS vaccines and therapeutics is still needed. Future Virology, 2013, 8, 1-2.	0.9	23
188	Design, Synthesis, and Biological Evaluation of Highly Potent Small Moleculeâ€"Peptide Conjugates as New HIV-1 Fusion Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2527-2539.	2.9	24
189	Small molecule fusion inhibitors: Design, synthesis and biological evaluation of (Z)-3-(5-(3-benzyl-4-oxo-2-thioxothiazolidinylidene)methyl)-N-(3-carboxy-4-hydroxy)phenyl-2,5-dimethylpyrroles and related derivatives targeting HIV-1 gp41. Bioorganic and Medicinal Chemistry, 2013, 21, 7539-7548.	1.4	32
190	Genomic signature and protein sequence analysis of a novel influenza AÂ(H7N9) virus that causes an outbreak in humans in China. Microbes and Infection, 2013, 15, 432-439.	1.0	78
191	Middle East respiratory syndrome coronavirus (MERS-CoV): challenges inÂidentifying its source and controlling its spread. Microbes and Infection, 2013, 15, 625-629.	1.0	79
192	Highly Pathogenic Avian Influenza A(H5N1) Mutants Transmissible by Air Are Susceptible to Human and Animal Neutralizing Antibodies. Journal of Infectious Diseases, 2013, 208, 1315-1319.	1.9	5
193	Approaches for Identification of HIV-1 Entry Inhibitors Targeting gp41 Pocket. Viruses, 2013, 5, 127-149.	1.5	46
194	Respiratory Syncytial Virus Entry Inhibitors Targeting the F Protein. Viruses, 2013, 5, 211-225.	1.5	64
195	Serological Investigation of Subclinical Influenza A(H7H9) Infection Among Healthcare and Non-Healthcare Workers in Zhejiang Province, China. Clinical Infectious Diseases, 2013, 57, 919-921.	2.9	16
196	Identification of a Receptor-Binding Domain in the S Protein of the Novel Human Coronavirus Middle East Respiratory Syndrome Coronavirus as an Essential Target for Vaccine Development. Journal of Virology, 2013, 87, 9939-9942.	1.5	168
197	3-Hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate inhibits HIV infection by blocking viral entry. Journal of Antimicrobial Chemotherapy, 2013, 68, 573-576.	1.3	11
198	Polyanionic Candidate Microbicides Accelerate the Formation of Semen-Derived Amyloid Fibrils to Enhance HIV-1 Infection. PLoS ONE, 2013, 8, e59777.	1.1	37

#	Article	IF	Citations
199	Identification of a Human Protein-Derived HIV-1 Fusion Inhibitor Targeting the gp41 Fusion Core Structure. PLoS ONE, 2013, 8, e66156.	1.1	6
200	Receptor-binding domain as a target for developing SARS vaccines. Journal of Thoracic Disease, 2013, 5 Suppl 2, S142-8.	0.6	52
201	The Outbreak of Avian Influenza A (H7N9) in China: Current Status and Future Prospects. Biomedical Journal, 2013, 36, 96.	1.4	6
202	Fusion. , 2013, , 1-9.		0
203	Tactics used by HIV-1 to evade host innate, adaptive, and intrinsic immunities. Chinese Medical Journal, 2013, 126, 2374-9.	0.9	3
204	Biosecurity and biosafety in research on emerging pathogens. Emerging Microbes and Infections, 2012, 1, 1-2.	3.0	6
205	Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerging Microbes and Infections, 2012, 1, 1-8.	3.0	36
206	Mutations of Gln64 in the HIV-1 gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the gp41 Pocket. Journal of Virology, 2012, 86, 589-593.	1.5	24
207	Design of highly potent HIV fusion inhibitors based on artificial peptide sequences. Chemical Communications, 2012, 48, 11579.	2.2	16
208	A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology, 2012, 9, 104.	0.9	57
209	HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain. Biochimica Et Biophysica Acta - Biomembranes, 2012, 1818, 2950-2957.	1.4	28
210	Design, synthesis, and biological activity of novel 1,4-disubstituted piperidine/piperazine derivatives as CCR5 antagonist-based HIV-1 entry inhibitors. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 3284-3286.	1.0	26
211	The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates. PLoS ONE, 2012, 7, e37019.	1.1	28
212	The Conserved Residue Arg46 in the N-Terminal Heptad Repeat Domain of HIV-1 gp41 Is Critical for Viral Fusion and Entry. PLoS ONE, 2012, 7, e44874.	1.1	6
213	Design, Synthesis, and Biological Activity of Novel 5-((Arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 Fusion Inhibitors Targeting gp41. Journal of Medicinal Chemistry, 2011, 54, 572-579.	2.9	81
214	HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies. PLoS ONE, 2011, 6, e18233.	1.1	32
215	In Vitro Selection and Characterization of HIV-1 Variants with Increased Resistance to Sifuvirtide, a Novel HIV-1 Fusion Inhibitor. Journal of Biological Chemistry, 2011, 286, 3277-3287.	1.6	47
216	A Novel Chimeric Protein-based HIV-1 Fusion Inhibitor Targeting gp41 Glycoprotein with High Potency and Stability. Journal of Biological Chemistry, 2011, 286, 28425-28434.	1.6	17

#	Article	IF	Citations
217	HIV-1 Glycoprotein 41 Ectodomain Induces Activation of the CD74 Protein-mediated Extracellular Signal-regulated Kinase/Mitogen-activated Protein Kinase Pathway to Enhance Viral Infection. Journal of Biological Chemistry, 2011, 286, 44869-44877.	1.6	8
218	Combinations of 3-Hydroxyphthalic Anhydride-Modified Ovalbumin With Antiretroviral Drug-Based Microbicide Candidates Display Synergistic and Complementary Effects Against HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, 384-392.	0.9	9
219	Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission. Retrovirology, 2010, 7, 37.	0.9	25
220	Novel Recombinant Engineered gp41 N-terminal Heptad Repeat Trimers and Their Potential as Anti-HIV-1 Therapeutics or Microbicides. Journal of Biological Chemistry, 2010, 285, 25506-25515.	1.6	51
221	Identification of a gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein as a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor. Journal of Virology, 2010, 84, 9359-9368.	1.5	19
222	The interaction between the membrane-proximal external region and the N-trimer region of HIV-1 gp41: Involvement in viral fusion. Science Bulletin, 2009, 54, 1707-1712.	4.3	0
223	The cytoplasmic domain of influenza M2 protein interacts with caveolin-1. Archives of Biochemistry and Biophysics, 2009, 486, 150-154.	1.4	12
224	Using gene expression databases for classical trait QTL candidate gene discovery in the BXD recombinant inbred genetic reference population: Mouse forebrain weight. BMC Genomics, 2008, 9, 444.	1.2	26
225	V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells. Vaccine, 2008, 26, 845-852.	1.7	8
226	Surface Exposure of the HIV-1 Env Cytoplasmic Tail LLP2 Domain during the Membrane Fusion Process. Journal of Biological Chemistry, 2008, 283, 16723-16731.	1.6	41
227	Identification of the HIV-1 gp41 Core-binding Motif in the Scaffolding Domain of Caveolin-1. Journal of Biological Chemistry, 2007, 282, 6143-6152.	1.6	40
228	Important Changes in Biochemical Properties and Function of Mutated LLP12 Domain of HIV-1 gp41. Chemical Biology and Drug Design, 2007, 70, 311-318.	1.5	9
229	A Potent Germline-Like Human Monoclonal Antibody Targeting a Novel pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. SSRN Electronic Journal, 0, , .	0.4	0